Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Sagimet Biosciences Series A (SGMT)?
Sagimet Biosciences Series A (SGMT) last closed at $10.43.
What is the market cap of Sagimet Biosciences Series A (SGMT)?
The market cap of Sagimet Biosciences Series A (SGMT) is approximately $739.6M.